---
keywords:
  - Multimodal Learning
  - Antibody Reformatting
  - Protein Language Models
  - Antibody Structural Context
category: cs.LG
publish_date: 2025-09-25
arxiv_id: 2509.19604
---

<!-- KEYWORD_LINKING_METADATA:
{
  "processed_timestamp": "2025-09-25T16:37:43.451313",
  "vocabulary_version": "1.0",
  "selected_keywords": [
    "Multimodal Learning",
    "Antibody Reformatting",
    "Protein Language Models",
    "Antibody Structural Context"
  ],
  "rejected_keywords": [],
  "similarity_scores": {
    "Multimodal Learning": 0.82,
    "Antibody Reformatting": 0.78,
    "Protein Language Models": 0.79,
    "Antibody Structural Context": 0.77
  },
  "extraction_method": "AI_prompt_based",
  "budget_applied": true,
  "candidates_json": {
    "candidates": [
      {
        "surface": "Multimodal Machine Learning",
        "canonical": "Multimodal Learning",
        "aliases": [
          "Multimodal ML"
        ],
        "category": "specific_connectable",
        "rationale": "Connects to recent trends in integrating multiple data types for enhanced predictive modeling.",
        "novelty_score": 0.55,
        "connectivity_score": 0.88,
        "specificity_score": 0.78,
        "link_intent_score": 0.82
      },
      {
        "surface": "Therapeutic Antibody Reformatting",
        "canonical": "Antibody Reformatting",
        "aliases": [
          "Therapeutic Antibody Conversion"
        ],
        "category": "unique_technical",
        "rationale": "Represents a specific application of machine learning in biotechnology, enhancing domain-specific connections.",
        "novelty_score": 0.75,
        "connectivity_score": 0.65,
        "specificity_score": 0.85,
        "link_intent_score": 0.78
      },
      {
        "surface": "Protein Language Models",
        "canonical": "Protein Language Models",
        "aliases": [
          "PLMs"
        ],
        "category": "unique_technical",
        "rationale": "Highlights the intersection of language models and protein analysis, a niche but growing research area.",
        "novelty_score": 0.68,
        "connectivity_score": 0.72,
        "specificity_score": 0.8,
        "link_intent_score": 0.79
      },
      {
        "surface": "Antibody Sequence and Structural Context",
        "canonical": "Antibody Structural Context",
        "aliases": [
          "Antibody Sequence Context"
        ],
        "category": "unique_technical",
        "rationale": "Emphasizes the importance of structural information in antibody engineering, facilitating targeted research links.",
        "novelty_score": 0.7,
        "connectivity_score": 0.6,
        "specificity_score": 0.82,
        "link_intent_score": 0.77
      }
    ],
    "ban_list_suggestions": [
      "reformatting success",
      "evaluation protocol",
      "real-world dataset"
    ]
  },
  "decisions": [
    {
      "candidate_surface": "Multimodal Machine Learning",
      "resolved_canonical": "Multimodal Learning",
      "decision": "linked",
      "scores": {
        "novelty": 0.55,
        "connectivity": 0.88,
        "specificity": 0.78,
        "link_intent": 0.82
      }
    },
    {
      "candidate_surface": "Therapeutic Antibody Reformatting",
      "resolved_canonical": "Antibody Reformatting",
      "decision": "linked",
      "scores": {
        "novelty": 0.75,
        "connectivity": 0.65,
        "specificity": 0.85,
        "link_intent": 0.78
      }
    },
    {
      "candidate_surface": "Protein Language Models",
      "resolved_canonical": "Protein Language Models",
      "decision": "linked",
      "scores": {
        "novelty": 0.68,
        "connectivity": 0.72,
        "specificity": 0.8,
        "link_intent": 0.79
      }
    },
    {
      "candidate_surface": "Antibody Sequence and Structural Context",
      "resolved_canonical": "Antibody Structural Context",
      "decision": "linked",
      "scores": {
        "novelty": 0.7,
        "connectivity": 0.6,
        "specificity": 0.82,
        "link_intent": 0.77
      }
    }
  ]
}
-->

# Improved Therapeutic Antibody Reformatting through Multimodal Machine Learning

## ğŸ“‹ ë©”íƒ€ë°ì´í„°

**Links**: [[daily_digest_20250925|20250925]] [[categories/cs.LG|cs.LG]]
**PDF**: [Download](https://arxiv.org/pdf/2509.19604.pdf)
**Category**: cs.LG
**Published**: 2025-09-25
**ArXiv ID**: [2509.19604](https://arxiv.org/abs/2509.19604)

## ğŸ”— ìœ ì‚¬í•œ ë…¼ë¬¸
- [[2025-09-23/Guided Sequence-Structure Generative Modeling for Iterative Antibody Optimization_20250923|Guided Sequence-Structure Generative Modeling for Iterative Antibody Optimization]] (85.4% similar)
- [[2025-09-19/Ensemble of Pathology Foundation Models for MIDOG 2025 Track 2_ Atypical Mitosis Classification_20250919|Ensemble of Pathology Foundation Models for MIDOG 2025 Track 2: Atypical Mitosis Classification]] (82.9% similar)
- [[2025-09-24/A deep reinforcement learning platform for antibiotic discovery_20250924|A deep reinforcement learning platform for antibiotic discovery]] (82.5% similar)
- [[2025-09-24/Learning Contrastive Multimodal Fusion with Improved Modality Dropout for Disease Detection and Prediction_20250924|Learning Contrastive Multimodal Fusion with Improved Modality Dropout for Disease Detection and Prediction]] (82.2% similar)
- [[2025-09-25/Dynamicasome_ a molecular dynamics-guided and AI-driven pathogenicity prediction catalogue for all genetic mutations_20250925|Dynamicasome: a molecular dynamics-guided and AI-driven pathogenicity prediction catalogue for all genetic mutations]] (81.8% similar)

## ğŸ·ï¸ ì¹´í…Œê³ ë¦¬í™”ëœ í‚¤ì›Œë“œ
**ğŸ”— Specific Connectable**: [[keywords/Multimodal Learning|Multimodal Learning]]
**âš¡ Unique Technical**: [[keywords/Antibody Reformatting|Antibody Reformatting]], [[keywords/Protein Language Models|Protein Language Models]], [[keywords/Antibody Structural Context|Antibody Structural Context]]

## ğŸ“‹ ì €ì ì •ë³´

**Authors:** 

## ğŸ“„ Abstract (ì›ë¬¸)

arXiv:2509.19604v1 Announce Type: new 
Abstract: Modern therapeutic antibody design often involves composing multi-part assemblages of individual functional domains, each of which may be derived from a different source or engineered independently. While these complex formats can expand disease applicability and improve safety, they present a significant engineering challenge: the function and stability of individual domains are not guaranteed in the novel format, and the entire molecule may no longer be synthesizable. To address these challenges, we develop a machine learning framework to predict "reformatting success" -- whether converting an antibody from one format to another will succeed or not. Our framework incorporates both antibody sequence and structural context, incorporating an evaluation protocol that reflects realistic deployment scenarios. In experiments on a real-world antibody reformatting dataset, we find the surprising result that large pretrained protein language models (PLMs) fail to outperform simple, domain-tailored, multimodal representations. This is particularly evident in the most difficult evaluation setting, where we test model generalization to a new starting antibody. In this challenging "new antibody, no data" scenario, our best multimodal model achieves high predictive accuracy, enabling prioritization of promising candidates and reducing wasted experimental effort.

## ğŸ“ ìš”ì•½

í˜„ëŒ€ ì¹˜ë£Œìš© í•­ì²´ ì„¤ê³„ëŠ” ë‹¤ì–‘í•œ ì¶œì²˜ì—ì„œ ìœ ë˜í•˜ê±°ë‚˜ ë…ë¦½ì ìœ¼ë¡œ ì„¤ê³„ëœ ê°œë³„ ê¸°ëŠ¥ ë„ë©”ì¸ì„ ì¡°í•©í•˜ëŠ” ë³µì¡í•œ í˜•ì‹ì„ í¬í•¨í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ í˜•ì‹ì€ ì§ˆë³‘ ì ìš© ê°€ëŠ¥ì„±ì„ í™•ì¥í•˜ê³  ì•ˆì „ì„±ì„ í–¥ìƒì‹œí‚¤ì§€ë§Œ, ê° ë„ë©”ì¸ì˜ ê¸°ëŠ¥ê³¼ ì•ˆì •ì„±ì´ ë³´ì¥ë˜ì§€ ì•Šì•„ ì „ì²´ ë¶„ìì˜ í•©ì„±ì´ ì–´ë ¤ìš¸ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í•´ê²°í•˜ê¸° ìœ„í•´, ìš°ë¦¬ëŠ” í•­ì²´ì˜ í˜•ì‹ ë³€í™˜ ì„±ê³µ ì—¬ë¶€ë¥¼ ì˜ˆì¸¡í•˜ëŠ” ë¨¸ì‹ ëŸ¬ë‹ í”„ë ˆì„ì›Œí¬ë¥¼ ê°œë°œí–ˆìŠµë‹ˆë‹¤. ì´ í”„ë ˆì„ì›Œí¬ëŠ” í•­ì²´ì˜ ì„œì—´ê³¼ êµ¬ì¡°ì  ë§¥ë½ì„ í†µí•©í•˜ì—¬ í˜„ì‹¤ì ì¸ ë°°í¬ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ë°˜ì˜í•˜ëŠ” í‰ê°€ í”„ë¡œí† ì½œì„ í¬í•¨í•©ë‹ˆë‹¤. ì‹¤ì œ í•­ì²´ ë³€í™˜ ë°ì´í„°ì…‹ ì‹¤í—˜ì—ì„œ, ëŒ€í˜• ì‚¬ì „ í•™ìŠµëœ ë‹¨ë°±ì§ˆ ì–¸ì–´ ëª¨ë¸(PLM)ì´ ë‹¨ìˆœí•œ ë„ë©”ì¸ ë§ì¶¤í˜• ë‹¤ì¤‘ ëª¨ë‹¬ í‘œí˜„ë³´ë‹¤ ì„±ëŠ¥ì´ ë–¨ì–´ì§„ë‹¤ëŠ” ë†€ë¼ìš´ ê²°ê³¼ë¥¼ ë°œê²¬í–ˆìŠµë‹ˆë‹¤. íŠ¹íˆ ìƒˆë¡œìš´ í•­ì²´ì— ëŒ€í•œ ì¼ë°˜í™”ê°€ í•„ìš”í•œ ê°€ì¥ ì–´ë ¤ìš´ í‰ê°€ ì„¤ì •ì—ì„œ, ìš°ë¦¬ì˜ ìµœì ì˜ ë‹¤ì¤‘ ëª¨ë‹¬ ëª¨ë¸ì€ ë†’ì€ ì˜ˆì¸¡ ì •í™•ë„ë¥¼ ë‹¬ì„±í•˜ì—¬ ìœ ë§í•œ í›„ë³´ë¥¼ ìš°ì„ ì‹œí•˜ê³  ì‹¤í—˜ì  ë…¸ë ¥ì„ ì¤„ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.

## ğŸ¯ ì£¼ìš” í¬ì¸íŠ¸

- 1. í˜„ëŒ€ ì¹˜ë£Œìš© í•­ì²´ ì„¤ê³„ëŠ” ë‹¤ì–‘í•œ ì¶œì²˜ì—ì„œ ìœ ë˜í•˜ê±°ë‚˜ ë…ë¦½ì ìœ¼ë¡œ ì„¤ê³„ëœ ê°œë³„ ê¸°ëŠ¥ ë„ë©”ì¸ì˜ ë‹¤ì¤‘ íŒŒíŠ¸ ì¡°í•©ì„ í¬í•¨í•©ë‹ˆë‹¤.
- 2. ë³µì¡í•œ í˜•ì‹ì€ ì§ˆë³‘ ì ìš© ê°€ëŠ¥ì„±ì„ í™•ì¥í•˜ê³  ì•ˆì „ì„±ì„ í–¥ìƒì‹œí‚¬ ìˆ˜ ìˆì§€ë§Œ, ê°œë³„ ë„ë©”ì¸ì˜ ê¸°ëŠ¥ê³¼ ì•ˆì •ì„±ì´ ë³´ì¥ë˜ì§€ ì•Šì•„ ì—”ì§€ë‹ˆì–´ë§ì— ì–´ë ¤ì›€ì„ ì¤ë‹ˆë‹¤.
- 3. ìš°ë¦¬ëŠ” í•­ì²´ì˜ í˜•ì‹ ë³€í™˜ ì„±ê³µ ì—¬ë¶€ë¥¼ ì˜ˆì¸¡í•˜ëŠ” ë¨¸ì‹ ëŸ¬ë‹ í”„ë ˆì„ì›Œí¬ë¥¼ ê°œë°œí•˜ì—¬ ì´ëŸ¬í•œ ë¬¸ì œë¥¼ í•´ê²°í•©ë‹ˆë‹¤.
- 4. ì‹¤ì œ í•­ì²´ ì¬êµ¬ì„± ë°ì´í„°ì…‹ ì‹¤í—˜ì—ì„œ ëŒ€í˜• ì‚¬ì „ í•™ìŠµëœ ë‹¨ë°±ì§ˆ ì–¸ì–´ ëª¨ë¸ì´ ë‹¨ìˆœí•˜ê³  ë„ë©”ì¸ ë§ì¶¤í˜• ë‹¤ì¤‘ ëª¨ë‹¬ í‘œí˜„ë³´ë‹¤ ì„±ëŠ¥ì´ ë–¨ì–´ì§€ëŠ” ê²°ê³¼ë¥¼ ë°œê²¬í–ˆìŠµë‹ˆë‹¤.
- 5. ìƒˆë¡œìš´ í•­ì²´ì— ëŒ€í•œ ë°ì´í„°ê°€ ì—†ëŠ” ì‹œë‚˜ë¦¬ì˜¤ì—ì„œ, ìš°ë¦¬ì˜ ìµœì ì˜ ë‹¤ì¤‘ ëª¨ë‹¬ ëª¨ë¸ì€ ë†’ì€ ì˜ˆì¸¡ ì •í™•ë„ë¥¼ ë‹¬ì„±í•˜ì—¬ ìœ ë§í•œ í›„ë³´ë¥¼ ìš°ì„ ì‹œí•˜ê³  ì‹¤í—˜ì  ë…¸ë ¥ì„ ì¤„ì…ë‹ˆë‹¤.


---

*Generated on 2025-09-25 16:37:43*